VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | PAPMET: MET inhibitors in treating papillary renal cell carcinoma

Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses the PAPMET study (NCT02761057), which is investigating MET inhibitors in patients with papillary renal cell carcinoma (pRCC). Patients treated with the MET inhibitor cabozantinib demonstrated improved median progression-free survival when compared to standard of care sunitinib. As a result, cabozantinib gained recognition as a standard of care option for patients with pRCC. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Tian Zhang, MD, has received research funding from Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics and Astellas; has been a speaker for Sanofi-Aventis and Genomic Health; has participated in advisory boards for Genentech/Roche, Merck, Exelixis, Sanofi-Aaventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Pharmacyclics, Seattle Genetics, Dendreon and Calithera; has done consultancy work for Bayer, Astra Zeneca, Foundation Medicine, IQVIA, MJH Associates, Pacific Genuity; and has familial connections to Nanorobotics, Capio Biosciences and Archimmune Therapeutics (spouse).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter